ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO906

The Association of Statins on Mortality of Patients With CKD Based on Two Large-Scale Databases

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • Ko, Gang Jee, Korea University College of Medicine and School of Medicine, Seoul, Korea (the Republic of)

The role of statins in CKD has been extensively evaluated, but it remains controversial in specific population such as dialysis-dependent CKD. This study examined the effect of statins on mortality in CKD patients using two large-scaled databases.


Database for the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) were formed from two hospitals. Medical records of patients admitted from 2002-2020 were extracted, which scored more than 2,000,000 cases from each hospital. As a sensitivity analysis, the results were validated with another large-scaled database, the Korea-National-Health-Insurance (KNHI) claims database constructed between 2003-2015. Multivariable Cox regression analyses were performed using adjustment with age, sex, and comorbidities.


Among 44,431 and 64,165 CKD patients of two hospitals, the numbers of statin users were 7,467 (16.80%) and 13,212 (20.59%). During the follow-up period for 8.9±5.8 and 9.5±5.6 years of each hospitals, statin users were associated with 67% and 61% lower all-cause mortality (Hazards ratios [95% confident interval], 0.33[0.30-0.36] and 0.39[0.33-0.42] respectively). Risk for Cardiovascular mortality were 78% lower in both hospital. In both centers, the risk of all-cause mortality was consistently reduced in statin users regardless of age, sex, renal function, and the presence of diabetes or hypertension (Fig 1). Risk difference was also analyzed in low-risk young patients (currently statins are not recommended), and the risks for all-cause and cardiovascular mortality were significantly lower among statin users even in low-risk patients aged under 50. When confirmatory analysis were performed in 4,114 CKD patients of KNHI data, statin in non-dialysis patients were associated with 59% lower risk of all-cause mortality. Dialysis patients showed similar results as 36% lower risks.


Statins were associated with lower mortality in CKD patients, regardless of dialysis status or other risk factors.